Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 109 clinical trials
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared With Carboplatin-Pemetrexed in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.

measurable disease
growth factor
pemetrexed
epidermal growth factor receptor
lung carcinoma
  • 1 views
  • 26 Aug, 2021
  • 285 locations
HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

This a phase II-III study. In the single-armed phase II period, HX008, a monoclonal antibody targeting PD-1, will be combined with pemetrexed+platinum (Investigators choice of cisplatin or

  • 0 views
  • 17 Feb, 2021
  • 10 locations
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a

neutrophil count
pemetrexed
osimertinib
carboplatin
gilbert's syndrome
  • 0 views
  • 31 Aug, 2021
  • 11 locations
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the …

measurable disease
HER2
growth factor
lung carcinoma
cancer chemotherapy
  • 3 views
  • 31 May, 2021
  • 98 locations
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

The aim of this clinical trial is to assess the effect of treatment with a monoclonal antibody called atezolizumab in patients diagnosed with a type of lung cancer called malignant pleural mesothelioma. The efficacy (whether the treatment works), safety and tolerability (side effects of treatment) of atezolizumab plus bevacizumab in …

  • 57 views
  • 14 May, 2021
  • 54 locations
Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer

The aims of this trial are to evaluate the efficacy and tolerability of pemetrexed + paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer.

measurable disease
antineoplastic
anaplastic thyroid carcinoma
iodine therapy
carcinoma
  • 12 views
  • 07 Nov, 2020
  • 1 location
Neoadjuvant IBI308 Bevacizumab Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC

The purpose of this study is to studying neoadjuvant IBI308, bevacizumab, plus pemetrexed and carboplatin followed by surgery to see how well it works in treating patients with unresectable

  • 0 views
  • 22 Jan, 2021
  • 1 location
Staggered Chemo-Immunotherapy With Durvalumab MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC

This is a Phase II, open label, randomized study of durvalumab in combination with pemetrexed and carboplatin in eligible adult patients with locally advanced or metastatic non-small cell lung

measurable disease
durvalumab
neutrophil count
pemetrexed
carboplatin
  • 0 views
  • 28 Jun, 2021
  • 1 location
Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

Currently the investigators have two different classes of second-line treatment options in recurrent non-small Cell Lung Cancer (NSCLC). In chemotherapy, docetaxel and pemetrexed

measurable disease
growth factor
neutrophil count
cancer chemotherapy
erlotinib
  • 9 views
  • 07 Nov, 2020
  • 1 location
A Phase I/II Study of Concurrent Pemetrexed/Cisplatin/Radiation in Stage IIIA/B Non-Small Cell Lung Cancer

The purpose of this study is to determine the safety and efficacy of the combination of pemetrexed and cisplatin given concurrently with high dose radiation treatment in patients with

pemetrexed
  • 32 views
  • 07 Nov, 2020
  • 1 location